PharmaMar inks licensing deal for Aplidin in Turkey
Spanish drugmaker PharmaMar (MC: PHM) has entered a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey.
Under the terms of the accord, PharmaMar will receive an undisclosed upfront payment as well as development milestones related to the health approval procedure of Aplidin in this country. PharmaMar will retain exclusive production rights and will supply the finished product to Eczacıbaşı for commercial use.
Aplidin is PharmaMar´s second most advanced anticancer drug currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma and in September 2016, PharmaMar presented to the European Medicines Agency the submission of the Marketing Authorization Application for this drug in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze